Advisory Alpha LLC Sells 773 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Advisory Alpha LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 54.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 659 shares of the medical research company's stock after selling 773 shares during the period. Advisory Alpha LLC's holdings in Thermo Fisher Scientific were worth $328,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Semus Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 4.0% during the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after acquiring an additional 18 shares during the period. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares in the last quarter. Proactive Wealth Strategies LLC boosted its stake in shares of Thermo Fisher Scientific by 2.7% during the 4th quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company's stock valued at $392,000 after buying an additional 20 shares during the period. Cassaday & Co Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 0.9% during the 4th quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock valued at $1,189,000 after acquiring an additional 20 shares in the last quarter. Finally, Callan Capital LLC increased its stake in shares of Thermo Fisher Scientific by 2.7% in the fourth quarter. Callan Capital LLC now owns 773 shares of the medical research company's stock worth $402,000 after acquiring an additional 20 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87% decrease in their position. The disclosure for this sale can be found here. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages recently commented on TMO. Raymond James reissued an "outperform" rating and issued a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Barclays reduced their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Finally, UBS Group lowered their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $607.43.

Thermo Fisher Scientific Stock Performance

TMO traded up $3.87 on Tuesday, hitting $400.34. 3,204,111 shares of the stock traded hands, compared to its average volume of 1,886,977. The business has a fifty day moving average price of $428.50 and a two-hundred day moving average price of $498.72. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The firm has a market capitalization of $151.13 billion, a PE ratio of 24.22, a P/E/G ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific's revenue was up .2% on a year-over-year basis. During the same period in the prior year, the company posted $5.11 earnings per share. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.